The Paris Stock Exchange closed up 0.75% on Tuesday, taking advantage of a new session without an indicator or major announcement to regain its senses and a little height after two difficult weeks.
The CAC 40 index rose 44.57 points to 5,964.66 points. The day before, it had already increased by 0.64%.
Never during the month of June had the Parisian rating chained two consecutive days of increases. On Tuesday, it even briefly regained 6,000 points at midday before declining somewhat.
The gains in Paris, as in all European markets, are “tepid and far from reversing the losses” of the past week, notes Michael Hewson of CMC Markets.
“Risk aversion remains high. We are not defeatist, but we are certainly not in a positive approach on the equity markets”, also describes to AFP Vincent Juvyns, head of market strategy at the within JP Morgan Asset Management.
He notes “a juxtaposition of headwinds”, notably with the risk that inflation will remain at a high rate, under the impetus of the war in Ukraine, and with the risks of recession due to the measures taken by central banks to limit price increases.
The stock market rebound benefited companies in various sectors and characteristics on the stock market, such as Air Liquide (+3.05% to 131.20 euros), Saint-Gobain (+2.48% to 45.07 euros after a fall by almost 4% on Monday), LVMH (+ 2.03% to 553.50 euros) or even BNP Paribas (+ 2.09% to 49.36 euros).
The French mining group Eramet announced on Tuesday that it had signed a contract for the sale of its subsidiary Aubert et Duval, a specialist in strategic metal alloys for aeronautics and nuclear, with a consortium made up of Airbus, Safran and Tikehau Ace Capital. The Eramet title took 7.43% to 111.30 euros.
The title of the retirement home group LNA Santé plunged 8.94% to 33.60 euros after the publication of information from RMC on an alleged health insurance fraud of nearly 1.2 million euros.
The company, which has around 80 establishments, has lost nearly a third of its stock market value since the start of the year, less than its biggest competitors Korian (-47%) and Orpea (-74%), criticized for the management of their establishments.
Valneva continued to rebound after announcing an 8.1% stake in US pharmaceutical giant Pfizer on Monday. The title still took more than 17% to 12.02 euros, an increase of 50% in two days. However, the action is still worth half as much as on January 1st.
© 2022 AFP
Did you like this article ? Share it with your friends with the buttons below.
